Human genomic DNA (HCC2157) (ATCC® CRL-2340D)

Organism: Homo sapiens, human  / 

Permits and Restrictions

View Restrictions

Product Format frozen Approx.10 µg
Storage Conditions -20°C or colder in a manual defrost freezer. Avoid freeze-thawing.
Biosafety Level 1
Introduction

Cell Line Description:

This cell line was initiated on March 4, 1996 from a 48 year-old Black female, and took 8 months to establish.  The tumor was classified as TNM stage IIIA, grade 2, ductal carcinoma with 1 out of 9 lymph node metastasis.  The cells form ducts and morula-like structures (hollow spherical structures lined with a single layer of cells).  The cells are positive for expression of Her2-neu and for expression of p53. HCC2157 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2) and for cytokeratin 19.  The cells are negative for expression of estrogen receptor (ER -), but positive for expression of progesterone receptor (PR +).  The DNA isolated from EBV-transformed lymphoblastoid cell line (HCC2157 BL) from the same patient is available as ATCC CRL-2341D.        

Quality Control Specifications

DNA Quality Control Information:

·         > 100 kb in size by agarose gel electrophoresis

·         No RNA detected in the agarose gel

·         A260/A280 ratio ³ 1.8

·         Tested and verified for PCR amplification and restriction digestion.

Basic Documentation
Restrictions The DNA is available with the following restrictions: 1. The CRL-2340 cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor DNA products derived from it may be sold or used for commercial purposes. Nor can the cells nor the DNA be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells and DNA are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the cells, DNA or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.